Clinical Trial Search

Phase 3 N=607 Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia

Prostatic Hyperplasia

Primary: Change From Baseline in International Prostate Symptom Score (IPSS) by Last Observation Carried Forward (LOCF) Approach at 24 Months — -4.07; -3.28; -3.73; -3.36 Score…

GlaxoSmithKline Results Apr 2019 16.6% serious AE View details

Phase 3 N=157 A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Leiomyoma · Uterine Hemorrhage

Primary: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment — 1.8; 47.2; 58.3 percentage of participants

Allergan Results Apr 2019 2.6% serious AE View details

Phase 3 N=424 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Uveitis

Primary: Number of Participants With Adverse Events — 398; 101 participants

AbbVie Results Apr 2019 23.8% serious AE View details

Phase 3 N=3,196 A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Avian Influenza

Primary: Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by Lot — 16.1; 17.0; 17.0; 128.6 geometric mean titer

Seqirus Results Apr 2019 7.4% serious AE View details

Phase 3 N=777 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

Diabetes · Diabetes Mellitus, Type 1

Primary: Change in the Percentage of HbA1c — 7.57; 7.58; 7.53; 0.06 Percentage of HbA1c — p=<0.001

Novo Nordisk A/S Results Apr 2019 3.5% serious AE View details

Phase 3 N=441 Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Transthyretin (TTR) Amyloid Cardiomyopathy

Primary: Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations — 8595; 5071 wins — p=0.0006

Pfizer Results Apr 2019 76.9% serious AE View details

Phase 3 N=210 A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

Systemic Sclerosis

Primary: Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period — -4.41; -6.14 Units on a scale — p=0.0983

Hoffmann-La Roche Results Apr 2019 12.3% serious AE View details

Phase 3 N=673 Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

HIV-1 Infection

Primary: Percentage of Participants Maintaining Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL — 90.8; 94.6 Percentage of Participants

Merck Sharp & Dohme LLC Results Apr 2019 4.4% serious AE View details

Phase 3 N=723 A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Squamous Non-Small Cell Lung

Primary: Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population…

Hoffmann-La Roche Results Apr 2019 48.1% serious AE View details

Phase 3 N=31 Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0 percentage of participants

Gilead Sciences Results Apr 2019 3.2% serious AE View details

Phase 3 N=1,315 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Bacterial Infections · Virus Diseases

Primary: Acceptability of Antibody (Ab) Response or Seroresponse Rates to All Antigens Contained in PR5I Vaccine One Month After the Toddler Dose of PR5I (11 to 12 Months of Age)…

MCM Vaccines B.V. Results Apr 2019 1.2% serious AE View details

Phase 3 N=12 Hydrocortisone for Term Hypotension

Infant, Newborn, Diseases · Cardiovascular Insufficiency

Primary: Death — 6; 6; 0; 0 Participants

NICHD Neonatal Research Network Results Apr 2019 8.3% serious AE View details

Phase 3 N=631 Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

Vaginal Dryness

Primary: Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12 — -23.7; -1.9 percentage of cells — p=<0.0001

Shionogi Results Apr 2019 1.3% serious AE View details

Phase 3 N=161 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Polycythemia Vera

Primary: Number of Participants With Adverse Events - All Grades — 143; 26 Participants

Novartis Pharmaceuticals Results Apr 2019 16.2% serious AE View details

Phase 3 N=211 Lubiprostone for Chronic Idiopathic Constipation Treatment

Constipation

Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 of Administration — 6.7; 5.2 number of SBM per week — p=0.020

Takeda Results Apr 2019 0.0% serious AE View details